← All trials
NCT05681260
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 6, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2029
- First posted
- Jan 12, 2023
- Last posted
- Feb 8, 2023
- Enrollment
- 200
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Children's Cancer Group, ChinaLead sponsor
- Capital Medical UniversityCollaborator
- Hebei UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Shandong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityOverall official - principal investigator
- Shenzhen UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Tongji UniversityCollaborator
- Sichuan UniversityCollaborator
- Wuhan Children's HospitalCollaborator
- Central South UniversityCollaborator
- Jiao Tong UniversityOfficial
- Sun Yat-Sen UniversityCollaborator
- Henan Provincial Cancer HospitalCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Zhejiang UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.